Tags

Type your tag names separated by a space and hit enter

Miltefosine Combined with Intralesional Pentamidine for Leishmania braziliensis Cutaneous Leishmaniasis in Bolivia.
Am J Trop Med Hyg. 2018 11; 99(5):1153-1155.AJ

Abstract

Bolivian cutaneous leishmaniasis due to Leishmania braziliensis was treated with the combination of miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 μg/mm2 lesion area on days 1, 3, and 5). Ninety-two per cent of 50 patients cured. Comparison to historic controls at our site suggests that the efficacy of the two drugs was additive. Adverse effects and cost were also additive. This combination may be attractive when a prime consideration is efficacy (e.g., in rescue therapy), avoidance of parenteral therapy, or the desire to treat locally and also provide systemic protection against parasite dissemination.

Links

Publisher Full Text
ncbi.nlm.nih.gov
ajtmh.org
PMC Free PDF

Authors+Show Affiliations

Soto J
FUNDERMA (Fundación Nacional de Dermatología), Santa Cruz, Bolivia.
Soto P
FUNDERMA (Fundación Nacional de Dermatología), Santa Cruz, Bolivia.
Ajata A
Servicio Departamental de Salud, Departamento de La Paz, La Paz, Bolivia.
Rivero D
Hospital Dermatológico de Jorochito, Santa Cruz, Bolivia.
Luque C
Servicio Departamental de Salud, Departamento de La Paz, La Paz, Bolivia.
Tintaya C
Servicio Departamental de Salud, Departamento de La Paz, La Paz, Bolivia.
Berman J
AB Foundation, North Bethesda, Maryland.

MeSH

AdultAntiprotozoal AgentsBoliviaDrug Therapy, CombinationFemaleHumansLeishmaniaLeishmania braziliensisLeishmaniasis, CutaneousMalePentamidinePhosphorylcholineTreatment Outcome

Pub Type(s)

Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

30255833

Citation

Soto, Jaime, et al. "Miltefosine Combined With Intralesional Pentamidine for Leishmania Braziliensis Cutaneous Leishmaniasis in Bolivia." The American Journal of Tropical Medicine and Hygiene, vol. 99, no. 5, 2018, pp. 1153-1155.
Soto J, Soto P, Ajata A, et al. Miltefosine Combined with Intralesional Pentamidine for Leishmania braziliensis Cutaneous Leishmaniasis in Bolivia. Am J Trop Med Hyg. 2018;99(5):1153-1155.
Soto, J., Soto, P., Ajata, A., Rivero, D., Luque, C., Tintaya, C., & Berman, J. (2018). Miltefosine Combined with Intralesional Pentamidine for Leishmania braziliensis Cutaneous Leishmaniasis in Bolivia. The American Journal of Tropical Medicine and Hygiene, 99(5), 1153-1155. https://doi.org/10.4269/ajtmh.18-0183
Soto J, et al. Miltefosine Combined With Intralesional Pentamidine for Leishmania Braziliensis Cutaneous Leishmaniasis in Bolivia. Am J Trop Med Hyg. 2018;99(5):1153-1155. PubMed PMID: 30255833.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Miltefosine Combined with Intralesional Pentamidine for Leishmania braziliensis Cutaneous Leishmaniasis in Bolivia. AU - Soto,Jaime, AU - Soto,Paula, AU - Ajata,Andrea, AU - Rivero,Daniela, AU - Luque,Carmelo, AU - Tintaya,Carlos, AU - Berman,Jonathan, PY - 2018/9/27/pubmed PY - 2019/9/10/medline PY - 2018/9/27/entrez SP - 1153 EP - 1155 JF - The American journal of tropical medicine and hygiene JO - Am J Trop Med Hyg VL - 99 IS - 5 N2 - Bolivian cutaneous leishmaniasis due to Leishmania braziliensis was treated with the combination of miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 μg/mm2 lesion area on days 1, 3, and 5). Ninety-two per cent of 50 patients cured. Comparison to historic controls at our site suggests that the efficacy of the two drugs was additive. Adverse effects and cost were also additive. This combination may be attractive when a prime consideration is efficacy (e.g., in rescue therapy), avoidance of parenteral therapy, or the desire to treat locally and also provide systemic protection against parasite dissemination. SN - 1476-1645 UR - https://www.unboundmedicine.com/medline/citation/30255833/Miltefosine_Combined_with_Intralesional_Pentamidine_for_Leishmania_braziliensis_Cutaneous_Leishmaniasis_in_Bolivia_ L2 - https://ajtmh.org/doi/10.4269/ajtmh.18-0183 DB - PRIME DP - Unbound Medicine ER -